{"title":"État des lieux sur les anti-IL-1 chez la femme enceinte","authors":"","doi":"10.1016/j.gofs.2024.04.004","DOIUrl":null,"url":null,"abstract":"<div><div>Anti-Interleukin-1 (Anti-IL-1) drugs are used to treat some chronic rheumatic diseases that can affect young people, including women of childbearing age. Two anti-IL-1 drugs are available in France: anakinra and canakinumab. Data on their use during pregnancy are still limited. Based on the published literature, we carried out a review of the use of these anti-IL-1 therapies during pregnancy: therapeutic indications, pharmacological profiles and assessment of embryonic, fetal and neonatal risks. Based on this analysis, and given the absence of any reported concern, it is possible to consider the use of these two treatments during pregnancy if the clinical situation so requires and under certain conditions. Based on the data available to date, anakinra should be preferred to canakinumab whenever possible.</div></div>","PeriodicalId":56056,"journal":{"name":"Gynecologie Obstetrique Fertilite & Senologie","volume":"52 11","pages":"Pages 657-662"},"PeriodicalIF":0.6000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecologie Obstetrique Fertilite & Senologie","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468718924001946","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Anti-Interleukin-1 (Anti-IL-1) drugs are used to treat some chronic rheumatic diseases that can affect young people, including women of childbearing age. Two anti-IL-1 drugs are available in France: anakinra and canakinumab. Data on their use during pregnancy are still limited. Based on the published literature, we carried out a review of the use of these anti-IL-1 therapies during pregnancy: therapeutic indications, pharmacological profiles and assessment of embryonic, fetal and neonatal risks. Based on this analysis, and given the absence of any reported concern, it is possible to consider the use of these two treatments during pregnancy if the clinical situation so requires and under certain conditions. Based on the data available to date, anakinra should be preferred to canakinumab whenever possible.
期刊介绍:
Gynécologie Obstétrique Fertilité & Sénologie est un mensuel scientifique d''information et de formation destiné aux gynécologues, aux obstétriciens, aux sénologues et aux biologistes de la reproduction. La revue, dans ses éditoriaux, articles originaux, mises au point, lettres à la rédaction et autres rubriques, donne une information actualisée ayant trait à l''obstétrique et à la gynécologie et aux différentes spécialités développées à partir de ces deux pôles : médecine de la reproduction, médecine maternelle et fœtale, périnatalité, endocrinologie, chirurgie gynécologique, cancérologie pelvienne, sénologie, sexualité, psychosomatique…